Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Assets: 2010-2025

Historic Current Assets for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $698.4 million.

  • Ani Pharmaceuticals' Current Assets rose 33.97% to $698.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $698.4 million, marking a year-over-year increase of 33.97%. This contributed to the annual value of $527.7 million for FY2024, which is 1.51% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Current Assets is $698.4 million, which was up 15.89% from $602.6 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Current Assets' 5-year high stood at $698.4 million during Q3 2025, with a 5-year trough of $182.8 million in Q1 2021.
  • For the 3-year period, Ani Pharmaceuticals' Current Assets averaged around $529.4 million, with its median value being $527.7 million (2024).
  • As far as peak fluctuations go, Ani Pharmaceuticals' Current Assets surged by 88.92% in 2021, and later fell by 0.79% in 2025.
  • Ani Pharmaceuticals' Current Assets (Quarterly) stood at $321.8 million in 2021, then increased by 6.99% to $344.3 million in 2022, then surged by 50.99% to $519.8 million in 2023, then rose by 1.51% to $527.7 million in 2024, then skyrocketed by 33.97% to $698.4 million in 2025.
  • Its last three reported values are $698.4 million in Q3 2025, $602.6 million for Q2 2025, and $536.3 million during Q1 2025.